Compare STKE & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | STKE | MDXH |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | Canada | Belgium |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.9M | 68.7M |
| IPO Year | 2021 | 2021 |
| Metric | STKE | MDXH |
|---|---|---|
| Price | $1.31 | $0.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $1.80 |
| AVG Volume (30 Days) | ★ 442.0K | 220.4K |
| Earning Date | 01-28-2027 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.10 |
| Revenue Next Year | N/A | $13.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $0.40 |
| 52 Week High | $3.95 | $5.33 |
| Indicator | STKE | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 20.10 |
| Support Level | $1.00 | N/A |
| Resistance Level | $1.37 | $0.64 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 9.02 | 0.47 |
Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.